Net profit of Biocon rose 472.91% to Rs 143.80 crore in the quarter ended December 2025 as against Rs 25.10 crore during the previous quarter ended December 2024. Sales rose 9.28% to Rs 4123.00 crore in the quarter ended December 2025 as against Rs 3773.00 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales4123.003773.00 9 OPM %20.2219.93 - PBDT740.90563.20 32 PBT225.60137.80 64 NP143.8025.10 473 Powered by Capital Market - Live News

Biocon announced the successful completion of a Qualified Institutions Placement (QIP), raising Rs 4,150 crore (~USD 460 million) through the issuance of 112,664,585 equity shares of face value Rs 5 each to eligible qualified institutional buyers at the issue price of Rs 368.35 per equity share (including a premium of Rs 363.35 per equity share). The QIP, which opened on 12 January 2026, and closed on 14 January 2026, attracted strong investor interest from a broad mix of domestic and international participants, reflecting robust confidence in Biocon`s growth prospects. The proceeds from the QIP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics, including repayment of debt availed in this regard. Biocon recently announced that its Board of Directors had approved a strategic corporate action to acquire all remaining minority shareholdings, including Viatris` stake, thereby making Biocon Biologics a wholly owned subsidiary of the Company.Powered by Capital Market - Live News

Biocon will hold a meeting of the Board of Directors of the Company on 12 February 2026.Powered by Capital Market - Live News

Biocon announced the launch of its GLP-1 peptide, Liraglutide, for diabetes (gVictoza�) and obesity (gSaxenda�), in the Netherlands through its distribution partner Pharmamedic B.V. The drug-device combination will be marketed in the Netherlands under the brand names Diavorin� for diabetes and Vobexoryn� for chronic weight management. The launch follows the approval from the Medicines Evaluation Board (MEB), Netherlands, earlier this year and will mark the first country in the European Union where the Company will directly launch Liraglutide under its own brand.Powered by Capital Market - Live News

Biocon announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 31 December 2025.Powered by Capital Market - Live News